This section of the site gives details of important safety warnings and messages for medicines including letters sent to help professionals in the event of major/urgent drug safety issues (Dear Healthcare Professional letters).
Latest safety warnings and messages for medicines
-
01 Feb 2012 | Information sent to healthcare professionals in January about the safety of medicines
Copies of letters sent to healthcare professionals in January 2012 to inform of new safety information and advice.
-
04 Jan 2012 | Information sent to healthcare professionals in December about the safety of medicines
Copies of letters sent to healthcare professionals in December 2011 to inform of new safety information and advice. This month's issues include risk of increased blood pressure and heart rate when using Strattera and information on weight gain, hyperglycaemia, and metabolic risk associated with Seroquel.
-
22 Dec 2011 | European Medicines Agency starts review of aliskiren-containing medicines following termination of ALTITUDE study - interim advice provided
Routine (non-urgent) review is recommended for patients taking aliskiren-containing medicines. Aliskiren is approved for the treatment of essential hypertension.
-
01 Dec 2011 | Information sent to healthcare professionals in November about the safety of medicines
Copies of letters sent to healthcare professionals in November 2011 to inform of new safety information and advice. This month's letters provide advice regarding Vectibix and Caelyx.
-
14 Nov 2011 | Liquid paracetamol for children: Revised UK dosing instructions have been introduced
Revised dosing instructions for children's liquid paracetamol products are now being introduced.
-
02 Nov 2011 | Information sent to healthcare professionals in October about the safety of medicines
Copies of letters sent to healthcare professionals in October 2011 to inform of new safety information and advice. This month's issues include restriction of use of Multaq and increased risk of mortality in paediatric patients with pulmonary arterial hypertension with the use of higher than recommended doses of Revatio.
-
03 Oct 2011 | Information sent to healthcare professionals in September about the safety of medicines
A copy of a letter about the risk of disease progression to acute myelogenous leukaemia in patients with myelodysplastic syndrome using romiplostim (Nplate).
-
28 Sep 2011 | Non-steroidal anti-inflammatory drugs (NSAIDs) and risk of heart problems
MHRA advice on the use of non-steroidal anti-inflammatory drugs (NSAIDs) remains the same despite a review by Hull York Medical School linking these drugs with an increased risk of heart attack or stroke.
-
14 Sep 2011 | Reboxetine: A review of the benefits and risks
A UK and Europe-wide review of scientific data has confirmed that reboxetine has benefit over placebo in its authorised indication for patients with severe or very severe depression.
-
05 Sep 2011 | Information sent to healthcare professionals in August about the safety of medicines
Copies of letters sent to healthcare professionals in August 2011 to inform of new safety information and advice.
